Invent Medic has started 2022 on the offence, with several new initiatives and focus on increasing sales of the two products in the Efemia family. So far, however, these initiatives have not translated into increased sales, as the sales figures for the first quarter 2022 remained largely unchanged compared to the same period 2021. Looking closer at the numbers, however, the company sees some promising signals, something that BioStock asked about when we contacted CEO Anna Lindström for a comment.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/05/unchanged-sales-figures-for-invent-medic-in-q1/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

https://news.cision.com/invent-medic-sweden/r/biostock--unchanged-sales-figures-for-invent-medic-in-q1,c3563412

(c) 2022 Cision. All rights reserved., source Press Releases - English